JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

Authors

• Pankit Vachhani, University of Alabama, Birmingham
• Ruben Mesa, Wake Forest University
• John Mascarenhas, Icahn School of Medicine at Mount Sinai
• Raajit Rampal, Memorial Sloan Kettering Cancer Center
• Stephen T. Oh, Washington University School of Medicine in St. Louis
• Alessandro Maria Vannucchi, University of Florence
• Maria Laura Fox, Vall d'Hebron University Hospital
• Francesca Palandri, Universitaria di Bologna
• Francesco Passamonti, Università degli Studi di Milano
• Jean-Jacques Kiladjian, Paris Cité University
• Mahshid Azimi, GSK plc
• Claire Harrison, Guy's and St Thomas' NHS Foundation Trust
• Prithviraj Bose, University of Texas MD Anderson Cancer Center

Journal

Haematologica

Publication Date

4-1-2026

Volume

111

Issue

4

First Page

1179

Last Page

1197

Document Type

Open Access Publication

DOI

10.3324/haematol.2025.288654

Rights and Permissions

Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica. 2026 Apr 1;111(4):1179-1197. doi: 10.3324/haematol.2025.288654. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recommended Citation

Vachhani, Pankit; Mesa, Ruben; Mascarenhas, John; Rampal, Raajit; Oh, Stephen T.; Vannucchi, Alessandro Maria; Fox, Maria Laura; Palandri, Francesca; Passamonti, Francesco; Kiladjian, Jean-Jacques; Azimi, Mahshid; Harrison, Claire; and Bose, Prithviraj, "JAK inhibitor selection in challenging scenarios of myelofibrosis: a review." Haematologica. 111, 4. 1179 - 1197. (2026).
https://digitalcommons.wustl.edu/oa_4/7621

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.